Navigation Links
Human Genome Sciences Presents New Data Showing Anti-Tumor Activity And Safety Of Trail Receptor Antibodies In Combination With Chemotherapy
Date:10/24/2007

n more than 20 patients, a number of whom remained on treatment for more than five months before progression of disease."

About the Preclinical Results in Cholangiocarcinoma

Results were also presented from preclinical studies that evaluated the ability of HGS-ETR1 and HGS-ETR2 to kill cancer cells and inhibit tumor growth as single agents and in combination with chemotherapy agents: cisplatin, gemcitabine or 5-fluorouracil. Efficacy was measured using cell toxicity assays in cholangiocarcinoma cell lines (in vitro) and in a xenograft cholangiocarcinoma tumor model (in vivo).

The in vitro study showed that HGS-ETR1 or HGS-ETR2 combined with either a pre-treatment or a co-treatment chemotherapy regimen induced additive or synergistic cytotoxicity. Co-treatment with the triplet combination of cisplatin, gemcitabine and either HGS-ETR1 or HGS-ETR2 was more effective than either single agent alone in all cell lines, with most triplet combinations inducing greater than 90 percent cell toxicity. In a xenograft model of cholangiocarcinoma, the combination of HGS-ETR1, cisplatin and gemcitabine significantly inhibited tumor growth, including tumor regression observed at a dose of 8 mg/kg of cisplatin.

About the HGS TRAIL Receptor Antibodies

HGS-ETR1 and HGS-ETR2 are agonistic human monoclonal antibodies that directly induce cancer-cell death by specifically binding to and activating the proteins known as TRAIL receptors 1 and 2, respectively. Using genomic techniques, HGS originally identified the TRAIL receptor-1 and TRAIL receptor- 2 proteins. The HGS-ETR1 and HGS-ETR2 antibodies were generated by HGS through collaboration with Cambridge Antibody Technology. HGS is developing HGS-ETR1 and HGS-ETR2 as potential treatments for a broad range of cancers.

GlaxoSmithKline (GSK) has exercised its option under a June 1996 agreement to develop and commercialize HGS-ETR1 jointly with HGS. Under the terms of the agreement, GSK and HGS will share e
'/>"/>

SOURCE Human Genome Sciences, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Testing for Human Papillomavirus
2. Bio-Matrix Scientifics Dr. ONeill Sees University of Pittsburghs Published Study on Culture Blood-Forming Stem Cells from Human Fat Tissue as Supporting Near Term Benefits of Banking Adipose (Fat) Derived Stem Cells
3. Phase II Results Show Once-Daily Dosing of Human GLP-1 Analog Liraglutide, Brings Patients to A1c Target
4. Apollos human proteins boost stem cell research
5. Advanced Cell Technology Develops First Human Embryonic Stem Cell Line without Destroying an Embryo
6. Modigene Announces Successful Completion of Pharmacokinetic & Pharmacodynamic Pre-Clinical Experiments for Proprietary Long-Acting Human Growth Hormone, Long-acting Interferon Beta and Long-acting Erythropoietin
7. Second Successful Quigley QR-443 Study Suggests Method of Action Relevant to Broad Range of Chronic Inflammatory Diseases - Human Study to Follow -
8. Research Documents Scalable Production, Survival Following Engraftment and Positive Impact on Cardiac Function in Infarcted Rats for Gerons Human Embryonic Stem Cell-Based Therapeutic for Heart Failure
9. Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B Showed Significant Reductions in Disease Activity in Patients with Active Systemic Lupus Erythematosus
10. NCI Researchers Discover Genes That Are Turned on at High Levels in Tumor-associated Blood Vessels of Mice and Humans
11. Research Indicates Gerons Human Embryonic Stem Cell-Based Therapeutic for Spinal Cord Injury Evades Direct Attack by the Human Immune System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... DUBLIN , January 15, 2014 Shire plc ... waived the Office of Fair Trading (OFT) approval condition to the ... Incorporated (NASDAQ: VPHM).   As a result of the ... Shire expects to complete the tender offer on January 24, 2014 ...
(Date:1/15/2014)... , Jan. 15, 2014  In an unprecedented effort to curb ... in ambulances and other transport vehicles, an advanced and portable UV ... personnel for the first time. In order to ... these deadly pathogens, West Palm Beach Fire ...
(Date:1/15/2014)... The Cadence Fitness & Health Center has been certified ... Association, a non-profit organization assisting medically integrated health and ... Fitness & Health Center is the only certified fitness ... Chicagoland area. "The certification means the Cadence ...
Breaking Medicine Technology:Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3Superbugs No Longer Ride In Rescue Vehicles 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 3
... Loss, Non-Inferiority in Target Vessel Failure and Low Rates of MACE ... ... PARK, Ill., April 22 A study published,in today,s Journal of ... Everolimus Eluting Coronary Stent System,in patients with coronary artery disease resulted ...
... Data For Presentation At ASCO 2008, LONDON ... a wide range of new data at the ... Chicago starting Friday, May,30th. The data cover a ... treatment and supportive care of cancer,patients. At this ...
Cached Medicine Technology:Study in JAMA Shows Patients Treated With Abbott's XIENCE(TM) V Drug Eluting Stent Experience Better Outcomes Than Patients Treated With Market-Leading Drug Eluting Stent 2Study in JAMA Shows Patients Treated With Abbott's XIENCE(TM) V Drug Eluting Stent Experience Better Outcomes Than Patients Treated With Market-Leading Drug Eluting Stent 3Study in JAMA Shows Patients Treated With Abbott's XIENCE(TM) V Drug Eluting Stent Experience Better Outcomes Than Patients Treated With Market-Leading Drug Eluting Stent 4Study in JAMA Shows Patients Treated With Abbott's XIENCE(TM) V Drug Eluting Stent Experience Better Outcomes Than Patients Treated With Market-Leading Drug Eluting Stent 5GlaxoSmithKline Reports Further Progress of Oncology Portfolio 2GlaxoSmithKline Reports Further Progress of Oncology Portfolio 3GlaxoSmithKline Reports Further Progress of Oncology Portfolio 4GlaxoSmithKline Reports Further Progress of Oncology Portfolio 5GlaxoSmithKline Reports Further Progress of Oncology Portfolio 6GlaxoSmithKline Reports Further Progress of Oncology Portfolio 7
(Date:4/17/2014)... PHILADELPHIA The presence of chronic inflammation in ... aggressive, prostate cancer, and this association was found ... levels, according to a study published in ... of the American Association for Cancer Research. , ... some participants of the placebo arm of the ...
(Date:4/17/2014)... PLOS Pathogens , children who live in regions of ... immune response to infection with malaria parasites that may ... and illness and partially control the growth of malaria ... develop future interventions that prevent or mitigate the disease ... 200 million cases of malaria occur worldwide, resulting in ...
(Date:4/17/2014)... McCullers, MD, was recently invited to submit a ... Reviews Microbiology , one of the world,s foremost ... disease specialist, and chair of the Department of ... Center, analyzed the epidemiology and microbiology of co-infections ... well as more recent 2009 novel H1N1 pandemic. ...
(Date:4/17/2014)... 16, 2014) The cause of neuronal death in ... proposes that neurons may be mistaken for foreign invaders ... to the way autoimmune diseases like type I diabetes, ... The study was published April 16, 2014, in ... likely controversial, idea in Parkinson,s disease; but if true, ...
(Date:4/17/2014)... An international team led by researchers at UC Davis ... plays a key role in cell division, also boosts ... the first time the complex has been shown to ... B1/Cdk1 an excellent target to control cellular energy production, ... was published online today in the journal Developmental ...
Breaking Medicine News(10 mins):Health News:Chronic inflammation may be linked to aggressive prostate cancer 2Health News:Chronic inflammation may be linked to aggressive prostate cancer 3Health News:Study sheds light on how the immune system protects children from malaria 2Health News:Is Parkinson's an autoimmune disease? 2Health News:Dual role: Key cell division proteins also power up mitochondria 2
... ... help dental practices increase their visibility & conversions online. , ... Oak Brook, IL (PRWEB) September 26, 2009 ... social networking program to help dental and medical practices gain higher visibility online and ...
... Brazilian wandering spider may improve erections, researchers say , ... discovered a novel way to treat erectile dysfunction -- ... bite from the Brazilian wandering spider (Phoneutria nigriventer) causes ... and later lead to impotence, researchers from the United ...
... in everything from problems with California,s hospitals to a perpetual ... the city will find itself deluged not only by smart ... solvers who tackle America,s greatest threats. The annual meeting of ... takes place at the San Diego Convention Center and the ...
... reports high success rate for new test, with results in ... new test can rapidly identify active tuberculosis in people who,ve ... half of all people with active TB, the disease-causing bacterium ... diagnostic tests are needed to help control the spread of ...
... created a new approach that vastly improves the ... organs. Kenneth Longmuir, associate professor of physiology ... & neurobiology, used liposomes, small spheres (less-than 100 ... "packages" for the cancer chemotherapeutic agent doxorubicin, and ...
... SEPT. 25, 2009 Journalists are invited to attend a ... care experts who will review and develop programs that may ... The symposium, which will be held Oct. 8 and 9 ... of Dimes, the American College of Obstetricians and Gynecologists, the ...
Cached Medicine News:Health News:Dental Website Marketing Firm, Officite, Launches Social Networking Program 2Health News:Dental Website Marketing Firm, Officite, Launches Social Networking Program 3Health News:Spider Venom -- The Next Way to Treat Impotence? 2Health News:4,000 numbers crunchers count on San Diego 2Health News:Faster Detection of TB May Be on the Horizon 2Health News:UCI researchers create new strategy for highly selective chemotherapy delivery 2Health News:Experts to review quality improvement programs to prevent preterm birth 2Health News:Experts to review quality improvement programs to prevent preterm birth 3
The Medtronic ULTRAFLEX™ venous cannula provides you with excellent cannula flexibility. This new, unique design provides easy maneuvering during placement and kink resistant flexibility during ...
... The DLP® One-Piece Pediatric Arterial ... in our line of pediatric ... advances over previous models such ... body and patented Flow-Guard™ introducer ...
... CAP® cannulae provides a simple solution ... An innovative combination of aortic perfusion ... the Select CAP® can provide a ... pressure readings on which you can ...
... the vitreoretinal surgeon a temporary tamponade for ... subretinal fluid, dissection of fibro-vascular proliferation and ... Eftiar Decalin liquid is indicated for use ... the retina. It is also indicated as ...
Medicine Products: